Navigation Links
New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
Date:11/7/2011

ely to severely active rheumatoid arthritis. Cimzia® in combination with MTX, is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying antirheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

For further information on UCB products, please visit www.UCB.com.

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

IMPORTANT SAFETY INFORMATION

Risk of Serious Infections and Malignancy

Patients treated with CIMZIA are at a
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Leaving the car ... public transit is good for your health, a new study ... United Kingdom and found that 76 percent of men and ... men and 11 percent of women used public transit, and ... or walked. Those who drove to work weighed more ...
(Date:8/20/2014)... According to a new market ... SPD, Liquid Crystal, Microblinds, Thermographic and Photochromics), by ... others), by geography - Global Forecast to 2014 ... Smart glass market was worth $1581.4 Million in ... by 2020, at an estimated CAGR of 20% ...
(Date:8/20/2014)... Raleigh, NC (PRWEB) August 20, 2014 Doctors ... a way to wipe out mesothelioma in laboratory mice by ... Mesothelioma has just posted details of the study on its ... , Scientists with Hong Kong University’s AIDS Institute of ... death protein 1” or PD-1. By altering DNA, the vaccine ...
(Date:8/20/2014)... New Jersey’s Medical Marijuana Program has ... tens of thousands of patients in the state. However, ... that would expand the list of qualifying conditions and ... summer by State Assemblywoman Linda Stender, the need to ... growing. , To help fill the information gap for ...
(Date:8/20/2014)... OR (PRWEB) August 20, 2014 August ... are urged to become educated about eye health and ... examined. One frequently overlooked eye condition that must be ... Sharon Kleyne Hour Power of Water radio show, is ... children increasing exponentially, childhood dry eye is becoming a ...
Breaking Medicine News(10 mins):Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3
... painkillers to treat inflammation are linked to an increased ... or flutter), concludes a study published on bmj.com ... drugs (NSAIDS) as well as new generation anti-inflammatory drugs, ... already been linked to an increased risk of heart ...
... Dennis Thompson HealthDay Reporter , SUNDAY, July 3 (HealthDay ... the summer air with dazzling colors and deafening sounds. But they ... year are harmed by fireworks, many of them maimed for life, ... care. "Where we see injuries is a lack of common ...
... N.C. July 4, 2011 Smoking cigarettes is a ... the smokers who choose to use one of the most ... the risk of serious cardiovascular events are on their way. ... Baptist Medical Center, in collaboration with researchers at Johns Hopkins ...
... Reinberg HealthDay Reporter , FRIDAY, July 1 (HealthDay ... are endorsing a U.S. health advisory panel,s recommendation that the ... breast cancer. The reason: There,s still a lack of ... Avastin was given fast-track approval by the U.S. ...
... The children most likely to walk or cycle to ... in an economically disadvantaged home, according to survey results that ... Pabayo of the University of Montreal Hospital Research Centre and ... is unique in that it follows the same group of ...
... the international aid community started to fund health programs ... support for tackling infectious diseases, and for implementing immunization ... and by governments are not always the same. New ... Globalization and Health uses ,agency theory, to examine ...
Cached Medicine News:Health News:Common painkillers linked to irregular heart rhythm 2Health News:Safety Experts Warn of Fireworks Dangers 2Health News:Safety Experts Warn of Fireworks Dangers 3Health News:Safety Experts Warn of Fireworks Dangers 4Health News:Chantix associated with 72 percent increased risk of serious CV events 2Health News: Avastin Rejection Supported by Cancer Experts 2Health News: Avastin Rejection Supported by Cancer Experts 3Health News: Avastin Rejection Supported by Cancer Experts 4Health News:Urban children are healthier commuters than rural teens 2Health News:Getting aid to where it is needed 2
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... Medicine Knot Pusher is a reusable instrument used ... Knot Pusher is utilized in the handling and ... two piece shaft allows the surgeon to place ... pushing. The ring handle allows the surgeon ease ...
Medicine Products: